Chubb Limited is the world's largest publicly traded property & casualty (P&C) insurer, headquartered in Zurich and operating across ~54 countries. Its core business is underwriting risk — commercial P&C for businesses of every size, high-net-worth personal lines (homes, collector cars, valuables), specialty lines (marine, cyber, financial, political risk), agriculture/crop insurance, global reinsurance (Chubb Tempest Re) and life insurance — and investing the "float" (premiums collected before claims are paid). What sets Chubb apart is underwriting discipline: it runs one of the lowest combined ratios of any scaled global insurer, so it profits on the insurance itself before earning a cent on its investment book. Led by Evan Greenberg and a 33-year dividend-raiser, it is a defensive compounder — and one of Berkshire Hathaway's largest holdings.
Lifecycle: Mature / Cash-generative compounder Sector: Financials · P&C Insurance
Chubb is scored on insurance economics, not industrial metrics — the primary lens is the combined ratio (claims + expenses ÷ premiums; below 100% = an underwriting profit), supported by operating ROE/ROTE, book-value growth, reserve adequacy and investment income. P/E off reported net income is deliberately de-emphasised: net income swings with mark-to-market bond gains/losses that say nothing about the underlying business.
| Sub-signal | Chubb (Q2'26 / TTM) | P&C peer norm | Score | Read |
|---|---|---|---|---|
| P&C combined ratio | 83.8% | 92–96% good | 96 | World-class underwriting; ~16pts of margin over a typical peer |
| Core operating EPS growth | +18.2% YoY ($7.26) | mid-single-digit | 88 | Underwriting income +18.8% to $1.94B; NII compounding |
| Core operating ROE / ROTE | 13.7% / 20.5% | ROE 10–14% | 82 | Top-tier returns on a conservatively-reserved book |
| Book value / share growth | +12.3% ($195.45) | mid-single-digit | 85 | TBVPS +17.1% to $131.93 — the real compounding engine |
| Premium growth (NPW) | +3.6% (P&C +3.0%, Life +7.5%) | flat–mid-single | 62 | Positive but decelerating as rate adequacy matures |
| Balance sheet | D/E 0.24 · int cover 14.1x | — | 85 | Fortress balance sheet; AA-rated; no distress |
Combined ratio 83.8% (Q2'26) · threshold <95% = 90–100 → Benchmark score 96/100. Chubb runs one of the lowest combined ratios of any scaled global P&C insurer — every point below 100 is underwriting profit before a cent of investment income. Peer median sits ~92–96%.
Moat average ~70 — a wide, durable moat built on cost/scale and brand rather than lock-in.
Chubb competes across commercial P&C, high-net-worth personal lines, and global specialty/reinsurance. The direct set is deep but the share picture is stable — Chubb wins on underwriting margin, not price. The moat sub-scores above are derived from this read: cost advantage stays high (best-in-class combined ratio), switching costs stay moderate (broker-intermediated).
| Rival | Threat type | Share trajectory | Moat-erosion vector |
|---|---|---|---|
| Travelers (TRV), AIG | Direct commercial P&C | Stable | Price competition as the hard market softens; Chubb defends on margin |
| Berkshire Hathaway specialty | Well-capitalised direct rival | Stable | Capacity/pricing pressure in large-account & specialty; also a large CB shareholder |
| Progressive (PGR) | Personal lines | Stable | Direct/tech-led auto pricing — less overlap with Chubb's HNW niche |
| Zurich, AXA, reinsurers | International / reinsurance | Stable | Global capacity; softening reinsurance renewals pressure specialty rates |
Net effect: Cost Advantage held at 80, Switching Costs 64 — a decelerating hard market is the watch-item, not share loss. Competitive threat: moderate; trajectory stable.
Capital allocation is a clear strength: 33rd consecutive annual dividend increase (raised 5.2% to $4.08/yr), a fresh $7.5B buyback authorisation, and disciplined M&A. Payout is a conservative ~14% of earnings, leaving ample capital to compound book value. External validation: Berkshire Hathaway holds an ~$11.2B stake and has been accumulating — Buffett/Abel's largest new build. FMP financial-health rating A- (4/5), corroborating high quality.
Insurers are valued on book value and combined-ratio-adjusted returns, never P/E off volatile reserves/investment marks. The anchor here is a justified P/Book from Chubb's own return on equity and the live discount rate; the guardrail floor for a balance-sheet insurer is P/TBV ≥ 3.0×.
Justified P/B = (ROE − g) ÷ (r − g), with core operating ROE 13.7%, discount rate r = 9.0% (10-Y 4.45% + 4.5% ERP + 0.0% high-quality add-on), and g = 6.0% → warranted P/B ≈ 2.57×.
Actual P/B = $354.03 ÷ BVPS $195.45 = 1.81× → actual÷warranted = 0.70× → ATTRACTIVE band (≤0.80).
Cross-check on tangible book: P/TBV = $354.03 ÷ TBVPS $131.93 = 2.68× (below the 3.0× rich line), against a justified P/TBV of ~4.8× on 20.5% ROTE → Attractive on both lenses. Band = Attractive, robust.
| Metric | Chubb | Reference | Read |
|---|---|---|---|
| P/Book (primary) | 1.81× | justified 2.57× | Attractive (0.70×) |
| P/Tangible book | 2.68× | rich line 3.0× | Below the guardrail; Attractive vs 4.8× justified |
| Clean P/E (core operating) | ~13.0× | S&P 500 ~32× | Deep discount to market; ~12× on reported net |
| Dividend yield (fwd) | 1.15% ($4.08) | + BVPS +12.3% | Low yield but the return is in book compounding + buybacks |
| PEG (clean) | ~1.4 | — | Fair for an 18% core-EPS grower |
Consensus $355.08 · median $356 · high $387 · low $301 (12 analysts last quarter, 9 last month). At $354.03 the stock trades essentially at consensus (+0.3% to it, +0.6% to median, +9.3% to the high) — the warranted-multiple anchor says cheap on fundamentals, but the Street has caught up to the near-term price, capping the consensus sub-factor at neutral. Grades: 1 Strong Buy / 22 Buy / 18 Hold / 2 Sell (Buy consensus, ~54% bullish); all recent actions were "maintain". FMP rating A-.
At $354 you also own, for little in the price: (1) rising net investment income as the ~$150B+ fixed-income book rolls into higher yields (higher-for-longer is a tailwind the low multiple ignores); (2) middle-market and Asia/international growth plus AI-driven underwriting/expense gains management is guiding to; (3) a $7.5B buyback retiring stock below justified value; and (4) the optionality of a re-rating toward the ~2.5× justified P/B. Net: the core business alone supports roughly the current price on the Street's numbers; the multiple re-rating + NII ramp are the ~free upside. A +3 to +5 tilt, not a re-rating of a cheap core.
Chubb's fortunes sit above its own execution on two external forces: the catastrophe-loss cycle & property-catastrophe pricing, and investment yields on the float. A third, related lever is the commercial P&C rate cycle (the hard market).
| Horizon | Read | Detail (source / date) |
|---|---|---|
| Historical (12–24m) | Tailwind | Multi-year hard market + rising rates drove record underwriting margin and NII (2023–25). |
| Current | Favourable / Neutral | 10-Y ~4.45–4.7% keeps reinvestment yields high (tailwind); combined ratio 83.8% (favourable). El Niño now active (macro 30 Jul) raises cat risk into the wind season. |
| Forward (6–12m) | Neutral | P&C pricing decelerating (NPW +3.0%); softening reinsurance renewals; cat risk elevated. Balanced by a firm NII trajectory. |
Driver score 63 — Neutral band (50–64). High investment yields and world-class underwriting are offset by decelerating pricing and rising El-Niño cat risk. Not eligible for amplification (needs ≥65) — the base BUY/HOLD signals stand unchanged. Thesis-invalidation floor: a major catastrophe year that pushes the P&C combined ratio sustainably above ~95%, or a credit-driven hit to the investment book.
The newest Macro-Economic report (30 Jul) maps Financials (XLF) Neutral across all three horizons in a 'Stagflation-lite' regime — a downgrade from the 20-Jul report's Tailwind read. Insurance is a relatively defensive sub-sector within Financials (beta 0.41, premium-repricing power as an inflation hedge, high reinvestment yields), which is why the conviction sits at the upper end of Neutral rather than lower — but the honest sector-map read is Neutral, not a Tailwind. With the driver at 63 (<65), no amplification would fire in any case; the base BUY/HOLD signals stand.
Source: sector-map (XLF) · Macro report 2026-07-30
Timing reads the tape, not the business. All five timeframes are in an uptrend (confluence strongly bullish), but daily momentum is fading and the stock has pulled back from its 28-Jul 52-week high of $365.91 to sit right on the $355 analyst consensus — a mild pause inside a primary uptrend rather than a fresh entry trigger.
| Factor | Reading | Score |
|---|---|---|
| MTF confluence | Strongly bullish (M/W/D/H/15m all up) | 78 |
| Daily momentum | RSI 54; MACD histogram negative (−1.13) — fading | 52 |
| Risk-reward | Stop ~$332 (−6.2%) vs base $377 (+6.5%) ≈ 1:1 | 55 |
| Relative strength | Near 52wk highs; up ~14% off the late-May low; XLF neutral | 66 |
| Sentiment | Grades all "maintain", Buy consensus; news mildly positive (Buffett accumulation, "12× bargain") | 58 |
| Catalyst density | Calm — no earnings for ~10wk (Q3 ~21 Oct); clustering ~70 | 70 |
Price $354 sits above SMA20 ($352), SMA50 ($340) and SMA200 ($320). Near-term resistance $356 then the $365.91 high; support $348, then $334. Timing 63 — constructive trend, but no fresh entry edge at consensus with momentum cooling.
| Date | Event | Impact | Forecast | Previous | Relevant? | Why |
|---|---|---|---|---|---|---|
| 2026-08-07 | Non-Farm Payrolls + Unemployment (Jul) | High | 80k / 4.2% | 57k / 4.2% | ⚠ Medium | Employment is medium-impact for a P&C insurer (Fed decisions/yield-curve are the high-impact events); affects rate path → investment income, not the near-term thesis |
| 2026-08-11 | Existing Home Sales (Jul) | High | 4.07M | 4.09M | No | Housing-linked, not P&C-relevant |
| ~2026-10-21 | Chubb Q3 2026 earnings | High | — | core $7.26 (Q2) | ✅ Yes | Next company catalyst — combined ratio, NII, cat losses |
| Date | Event | Actual | Forecast | Surprise | Impact |
|---|---|---|---|---|---|
| 2026-08-06 | Initial Jobless Claims | 199k | 202k | Below (good) | Labour still firm — neutral for CB |
| 2026-08-06 | Nonfarm Productivity Q2 | 1.4% | 0.6% | Above | Mildly disinflationary — neutral for CB |
| 2026-07-21 | Chubb Q2 2026 print | core $7.26 (+18.2%) | — | Beat / in-line | Combined ratio 83.8%, BVPS +12.3% — already in the last report |
Chubb is a High-macro-sensitivity Financials name, so the §8 3-day rule is checked explicitly: today's High-impact NFP/Unemployment print is only medium-impact for a P&C insurer (its rate sensitivity runs through the multi-year investment book, and Fed decisions — not a single jobs print — are the high-impact events for the sector). The short signal is already HOLD, so no WAIT-for-event override is warranted and the +14d schedule stands. The genuine company catalyst is Q3 earnings in ~10 weeks.
| Timeframe | Trend | Direction | RSI | MACD | Key S/R | Breakout | Vol |
|---|---|---|---|---|---|---|---|
| Monthly | Uptrend | Bullish | 66.7 | + rising | S 252 / R 346 | Resist. breakout | 0.2x |
| Weekly | Uptrend | Bullish | 60.8 | + rising | S 296 / R 365 | Resist. breakout | 0.8x |
| Daily | Strong uptrend | Bullish | 54.3 | − fading | S 334 / R 356 | — | 0.8x |
| Hourly | Uptrend | Bullish | 58.3 | + flat | S 347 / R 358 | — | 0.2x |
| 15-min | Strong uptrend | Bullish | 60.5 | + flat | S 350 / R 358 | — | 0.4x |
| Confluence: Strongly Bullish · MTF Score 78 | |||||||
Every timeframe is in an uptrend and price ($354) is above its 20-, 50- and 200-day averages ($352 / $340 / $320) — a healthy primary trend. The one caution is the daily MACD histogram turning negative after the pullback from the 28-Jul 52-week high ($365.91). This is a textbook pause within an uptrend, not a breakdown: watch a reclaim of $356 (momentum re-igniting) or a pullback into $348/$334 support (a better entry) rather than chasing here.
CB 6-month daily with SMA50. Ran to a 52-week high of $365.91 on 28 Jul (post-Q2), then eased to $354 — sitting on the $355 analyst consensus.
Hard market persists longer than feared, a benign catastrophe year, and net investment income accelerates as the fixed-income book rolls into higher-for-longer yields. Multiple re-rates toward the ~2.1× P/B implied by 13.7% ROE; the $7.5B buyback and continued Berkshire accumulation add support. ~+16%.
The most probable path: combined ratio stays in the low-to-mid 80s, NPW grows mid-single-digit, NII keeps compounding, and book value grows ~10–12%. The stock tracks book-value growth plus a modest re-rating toward the justified multiple. ~+6.5% price plus the dividend.
An insurer-specific downside, NOT an AI/index de-rating (Chubb is not AI-levered, beta 0.41, and its earnings are understated — not inflated — by non-operating marks). Triggers: a major catastrophe year (the now-active El Niño into wind season) blows out the combined ratio; loss-cost inflation from tariffs/stagflation compresses margins; and a risk-off / private-credit crack (an armed macro tail) marks down the investment book. ~−15%.
Forecast: Fundamental group is MET now. Technical group: a reclaim of $356 could come within 1–2 weeks if the tape firms (Moderate confidence); the cleaner setup is a pullback into $348/$334 support (Moderate). Catalyst group is event-dependent — unlikely before Q3 earnings ~21 Oct (Unlikely near-term). Net: with 1 of 3 groups met the ladder reads Half-Size — a starter here, scale the balance on the technical confirmation.
Forecast: Stop-loss unlikely in the next 4–6 weeks — $332 is ~6% below spot and below the rising 50-day ($340); it would take a cat event or a broad risk-off flush. Profit-trim not live (price below target, RSI 54). No exit trigger currently live → Hold.
What you're risking: the Technical entry group is not met — you'd be buying at the $355 analyst consensus with daily momentum fading, so near-term the downside to the $332 stop (~−6.2%) is real if the pullback deepens toward $334 support. The bear case (~$300, −15%) needs a major cat year or a credit shock.
What you're gaining: immediate participation in a best-in-class compounder at 1.81× book vs 2.57× justified — you start capturing the ~10–12% annual book-value growth, the growing dividend + $7.5B buyback, and the re-rating optionality, plus you own a defensive (beta 0.41) name Berkshire keeps buying. Read: a reasonable half-size starter; waiting for a $356 reclaim or a dip into $348/$334 materially improves the entry.
What you're giving up: the base path to $377 and the compounding of a name trading below its justified multiple — selling here means selling a high-quality insurer at Attractive value, not an expensive one.
What you're protecting: only the near-term path risk (momentum cooling at the highs, an active El Niño into wind season). No exit rule is live — no stop hit, no thesis break, RSI below 70 — so there is no mechanical reason to sell. This is a hold / accumulate-on-weakness zone, not a sell.
Position sizing not computed — no risk budget or portfolio role was specified for this watchlist refresh. For context only: the §12 Conviction Ladder reads Half-Size (1 of 3 entry paths met), ATR is ~$7.7/day (~2.2%), and beta is a low 0.41, so CB behaves as a low-volatility, defensive holding. Specify an allocation for sizing guidance.
{
"ticker": "CB",
"date": "2026-08-07",
"version": "v6",
"exchange": "NYSE",
"exchange_ticker": "NYSE:CB",
"isin": "CH0044328745",
"api_ticker": "CB",
"company": "Chubb Limited",
"currency": "USD",
"brand": "Chubb",
"sector": "Financials",
"sub_industry": "Insurance \u2014 Property & Casualty",
"lifecycle_stage": "mature",
"price_at_rating": 354.03,
"signal_short": "HOLD",
"signal_medium": "BUY",
"signal_long": "BUY",
"primary_signal": "BUY",
"short_hold_reason": "technical_pending",
"quality_score": 84,
"valuation_score": 72,
"timing_score": 63,
"driver_score": 63,
"overall_confidence": 60,
"economic_alignment_stance": "Neutral",
"economic_alignment_conviction": 58,
"economic_alignment_pressure": "Neutral",
"economic_alignment_source": "sector-map",
"macro_report_date": "2026-07-30",
"val_multiple_basis": "P/Book (core-ROE justified)",
"warranted_multiple": 2.57,
"actual_multiple": 1.81,
"warranted_ratio": 0.7,
"val_band": "attractive",
"discount_rate_r": 0.09,
"risk_free_10y": 0.0445,
"g_near": 0.06,
"g_term": 0.03,
"actual_ptbv_reported": 2.68,
"nonop_pct_of_net_income": 5.0,
"clean_pe": 13.0,
"clean_peg": 1.4,
"combined_ratio": 83.8,
"core_operating_roe": 13.7,
"rote": 20.5,
"bvps": 195.45,
"tbvps": 131.93,
"bvps_growth_yoy": 12.3,
"q2_core_eps": 7.26,
"reported_net_eps_q2": 7.3,
"competitive_share_trajectory": "stable",
"competitive_threat_level": "moderate",
"driver_commodity_trend": null,
"hard_gate_state": "clear",
"gates_triggered": [],
"do_not_buy_triggers": [],
"entry_groups_met": 1,
"entry_conviction": "Half-Size",
"exit_groups_live": 0,
"exit_action": "Hold",
"short_entry_confirmed": false,
"short_cap_reason": "Short base BUY (Fundamental path \u2014 cheap on book value) capped to HOLD: Technical AND Catalyst groups both unmet (daily MACD histogram negative; no >+5% earnings catalyst). Buy on confirmation \u2014 a reclaim of $356 on volume, or a pullback into $348/$334 support.",
"fair_value_est": 370.0,
"stop_loss": 332.0,
"target_price": 377.0,
"scenario_base_target": 377,
"scenario_bull_target": 410,
"scenario_bear_target": 300,
"analyst_consensus_target": 355.08,
"analyst_target_high": 387,
"analyst_target_low": 301,
"analyst_target_upside_pct": 0.3,
"analyst_grades_consensus": "Buy",
"analyst_bullish_pct": 53.5,
"analyst_coverage_count": 12,
"fmp_rating": "A-",
"fmp_overall_score": 4,
"recent_upgrades_30d": 0,
"recent_downgrades_30d": 0,
"next_update_date": "2026-08-21",
"next_update_basis": "default +14d (Q3 earnings ~2026-10-21 beyond window; today's NFP is medium-impact for a P&C insurer, not a scheduling trigger)",
"next_check_date": "2026-08-21",
"analysis_status": "on-going",
"finder_ticker": "CB",
"finder_exchange": "\ud83c\uddfa\ud83c\uddf8 NYSE"
}
Steady-state +14d refresh: signals held (S HOLD, M BUY, L BUY); the only material change is Economic Alignment stepping from Tailwind to Neutral on the newest macro sector map.